FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138807112> ?p ?o ?g. }

• W3138807112 endingPage "509" @default.
• W3138807112 startingPage "501" @default.
• W3138807112 abstract "PURPOSE The objectives of the study were to characterize the tumor burden dynamics on serial computed tomography scans in patients with advanced non–small-cell lung cancer treated with first-line pembrolizumab and to identify imaging markers for prolonged overall survival (OS). MATERIALS AND METHODS Eighty-eight patients treated with first-line pembrolizumab monotherapy were evaluated on serial computed tomography scans to characterize their quantitative tumor burden during therapy. Tumor burden dynamics were studied for the association with OS. RESULTS The overall response rate was 42% (37/88), with the median tumor burden changes at the best overall response of −18.3% (range, −100.0% to +103.6%). Response rates were higher in men than in women ( P = .05) and in patients with higher programmed cell death ligand-1 expression levels ( P = .02). Tumor burden stayed below the baseline burden throughout therapy in 55 patients (63%). In an 8-week landmark analysis, patients with tumor burden below the baseline burden during the first 8 weeks of therapy had longer OS compared with patients who had ≥ 0% increase (median OS, 30.7 v 16.2 months; hazard ratio [HR] = 0.44; P = .01). In the extended Cox models, patients whose tumor burden stayed below the baseline burden throughout therapy had significantly reduced hazards of death (HR = 0.41, P = .003, univariate; HR = 0.35, P = .02, multivariate). Only one patient (1.1%) experienced pseudoprogression with initial tumor increase and subsequent tumor regression. CONCLUSION In patients with advanced non–small-cell lung cancer treated with first-line single-agent pembrolizumab, tumor burden reduction below the baseline burden during therapy was an independent marker for prolonged OS, which may serve as a practical guide for treatment decisions." @default.
• W3138807112 created "2021-03-29" @default.
• W3138807112 creator A5030450694 @default.
• W3138807112 creator A5065789326 @default.
• W3138807112 creator A5069854182 @default.
• W3138807112 creator A5075568815 @default.
• W3138807112 creator A5086249998 @default.
• W3138807112 date "2021-11-01" @default.
• W3138807112 modified "2023-10-16" @default.
• W3138807112 title "Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non–Small-Cell Lung Cancer" @default.
• W3138807112 cites W1971098726 @default.
• W3138807112 cites W1982488143 @default.
• W3138807112 cites W2019607817 @default.
• W3138807112 cites W2059426108 @default.
• W3138807112 cites W2068549626 @default.
• W3138807112 cites W2092147241 @default.
• W3138807112 cites W2095084483 @default.
• W3138807112 cites W2099173339 @default.
• W3138807112 cites W2100158834 @default.
• W3138807112 cites W2102571808 @default.
• W3138807112 cites W2104347254 @default.
• W3138807112 cites W2106511606 @default.
• W3138807112 cites W2109117547 @default.
• W3138807112 cites W2115113482 @default.
• W3138807112 cites W2122506368 @default.
• W3138807112 cites W2139248078 @default.
• W3138807112 cites W2143488876 @default.
• W3138807112 cites W2153778867 @default.
• W3138807112 cites W2198093519 @default.
• W3138807112 cites W2218718059 @default.
• W3138807112 cites W2293531514 @default.
• W3138807112 cites W2468576628 @default.
• W3138807112 cites W2527905628 @default.
• W3138807112 cites W2529904548 @default.
• W3138807112 cites W2554618897 @default.
• W3138807112 cites W2556154467 @default.
• W3138807112 cites W2560367415 @default.
• W3138807112 cites W2572174216 @default.
• W3138807112 cites W2592144107 @default.
• W3138807112 cites W2622525620 @default.
• W3138807112 cites W2725398806 @default.
• W3138807112 cites W2727175430 @default.
• W3138807112 cites W2783708539 @default.
• W3138807112 cites W2804340200 @default.
• W3138807112 cites W2891266481 @default.
• W3138807112 cites W2892640821 @default.
• W3138807112 cites W2901654380 @default.
• W3138807112 cites W2925446385 @default.
• W3138807112 cites W3047211233 @default.
• W3138807112 doi "https://doi.org/10.1200/po.20.00478" @default.
• W3138807112 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8232801" @default.
• W3138807112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34250409" @default.
• W3138807112 hasPublicationYear "2021" @default.
• W3138807112 type Work @default.
• W3138807112 sameAs 3138807112 @default.
• W3138807112 citedByCount "4" @default.
• W3138807112 countsByYear W31388071122022 @default.
• W3138807112 crossrefType "journal-article" @default.
• W3138807112 hasAuthorship W3138807112A5030450694 @default.
• W3138807112 hasAuthorship W3138807112A5065789326 @default.
• W3138807112 hasAuthorship W3138807112A5069854182 @default.
• W3138807112 hasAuthorship W3138807112A5075568815 @default.
• W3138807112 hasAuthorship W3138807112A5086249998 @default.
• W3138807112 hasBestOaLocation W31388071121 @default.
• W3138807112 hasConcept C121608353 @default.
• W3138807112 hasConcept C126322002 @default.
• W3138807112 hasConcept C143998085 @default.
• W3138807112 hasConcept C144301174 @default.
• W3138807112 hasConcept C207103383 @default.
• W3138807112 hasConcept C2776256026 @default.
• W3138807112 hasConcept C2777701055 @default.
• W3138807112 hasConcept C2780057760 @default.
• W3138807112 hasConcept C38180746 @default.
• W3138807112 hasConcept C44249647 @default.
• W3138807112 hasConcept C50382708 @default.
• W3138807112 hasConcept C71924100 @default.
• W3138807112 hasConceptScore W3138807112C121608353 @default.
• W3138807112 hasConceptScore W3138807112C126322002 @default.
• W3138807112 hasConceptScore W3138807112C143998085 @default.
• W3138807112 hasConceptScore W3138807112C144301174 @default.
• W3138807112 hasConceptScore W3138807112C207103383 @default.
• W3138807112 hasConceptScore W3138807112C2776256026 @default.
• W3138807112 hasConceptScore W3138807112C2777701055 @default.
• W3138807112 hasConceptScore W3138807112C2780057760 @default.
• W3138807112 hasConceptScore W3138807112C38180746 @default.
• W3138807112 hasConceptScore W3138807112C44249647 @default.
• W3138807112 hasConceptScore W3138807112C50382708 @default.
• W3138807112 hasConceptScore W3138807112C71924100 @default.
• W3138807112 hasIssue "5" @default.
• W3138807112 hasLocation W31388071121 @default.
• W3138807112 hasLocation W31388071122 @default.
• W3138807112 hasLocation W31388071123 @default.
• W3138807112 hasOpenAccess W3138807112 @default.
• W3138807112 hasPrimaryLocation W31388071121 @default.
• W3138807112 hasRelatedWork W1975698825 @default.
• W3138807112 hasRelatedWork W1984291133 @default.
• W3138807112 hasRelatedWork W2092721488 @default.
• W3138807112 hasRelatedWork W2094620610 @default.

• next